Multiple Sclerosis Clinical Trial
A Study to Assess New Participant’s Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments
Summary
The primary objective of the study is to understand what the added value of natalizumab (Tysabri®) treatment is from a participant's perspective at a given time, based on a one-shot survey. The secondary objectives of the study also aim to characterize the participant's decision-making process to get the treatment; the burden of treatment, characterization of the study population, assessment of the quality of life (QoL), and fatigue dimension.
Eligibility Criteria
Inclusion Criteria:
• Participants diagnosed with RRMS and followed by a neurologist in France.
Exclusion Criteria:
• Lack of literacy
Note: Other protocol-defined Inclusion/Exclusion criteria may apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Cambridge Massachusetts, 02142, United States
How clear is this clinincal trial information?